A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metas
- This topic has 3 replies, 3 voices, and was last updated 10 years, 8 months ago by
.
-
Posts
-
Hello again Gavin,
As I mentioned on the PDT thread, My husband was diagnosed with locally advanced cholangiocarcinoma in January of this year. He is about to begin his third round of Chemotherapy. However, this is another trial of great interest to me, especially since Regorafenib has Health Canada approval and should be available here. But once again, I am completely naïve of the process for participating in a clinical trial. Got any advice?Thanks for that Percy. Let’s hope that the trial shows positive results and is of benefit to CC patients. Yep I’ll say hi to my mum for you when I go back round to get her breakfast done in an hour or so. Yes it sure has been a memorable winter on both sides of the pond this year. You guys are getting the snow and ice, and here, down south they have had constant flooding and storms.
Stay warm!
Gavin
Hi, everyone,
Thanks to Gavin, this may be one of those clinical trial that can be of benefits to CCA patients especially if you have done the Target Now or Foundation One NGS genomics profile already; if you have amplification ,over-expressions or actual mutations. it seems base on the criteria, the restriction are minimalto join.
Regorafenib isa FDA approved for other cancer but can be “off label use” for other solid tumor; its basic dose and side effects are mostly known.Godd job, Gavin, BTW, please say hi to your mum for me, boy, is it a memorable winter here in the States or what”?
God bless.
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy.
- The forum ‘Clinical Trials’ is closed to new topics and replies.